Diligence memo · auto-generated · as of July 2, 2026
Slate Bio, Inc.
Slate Bio, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Slate Bio, Inc. operates in Biotech / Pharma, based in CHARLOTTESVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Slate Bio, Inc. has raised $4.8M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.8M on 2022-12-30.
Most recent recorded round closed around 2022-12-30.
Valuation (modeled)modeled
Provath models Slate Bio, Inc. at approximately $30M (range $2.0M–$120M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.74× the median modeled value of Seed Biotech / Pharma companies in 2022–2024 (14 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 3.5 yr ago; this sector typically re-raises about every 15 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 2.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 48% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 52% of those peers.
Closest niche peers: Outer Biosciences, LLC, CASS Pharmaceuticals, Inc., FOOP Organic Biosciences, Inc., Trio Pharmaceuticals, Inc., Aruka Bio, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.